Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: Infants with predisposing conditions

Pediatric Infectious Disease Journal

Volumn 22, Issue SUPPL. 2, 2003, Pages

  Weisman, Leonard E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Low birth weight; Prematurity

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; VITAMIN;

AIRWAY OBSTRUCTION; BRONCHIOLITIS; CHRONIC LUNG DISEASE; CONFERENCE PAPER; DISEASE PREDISPOSITION; DISEASE SEVERITY; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; INFANT; LOW BIRTH WEIGHT; LOWER RESPIRATORY TRACT INFECTION; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG MECHANICS; LUNG VASCULAR RESISTANCE; MORTALITY; MULTIPLE PREGNANCY; NEWBORN CARE; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SURVIVAL; VERY LOW BIRTH WEIGHT; VIRUS INFECTION; VITAMIN SUPPLEMENTATION;

AIRWAY OBSTRUCTION; FEMALE; GESTATIONAL AGE; HUMANS; INCIDENCE; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; LUNG DISEASES; MALE; MORBIDITY; MULTIPLE BIRTH OFFSPRING; POSITIVE-PRESSURE RESPIRATION; PROGNOSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; VASCULAR RESISTANCE;

EID: 0037323511     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200302001-00005     Document Type: Conference Paper

References (59)

1. Aujard Y, Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 2002;96:S9-14.
2. US Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics Reports. Births: final data for 1998. NVSS 2000;48:1-99.
3. Hoyert DL, Freedman MA, Strobino DM, et al. Annual summary of vital statistics: 2000. Pediatrics 2001;108:1241-55.
4. Bont L, Kimpen JL. Immunological mechanisms of severe respiratory syncytial virus bronchiolitis. Intensive Care Med 2002;28:616-21.
5. Evans HE, Akpata SO, Glass L. Serum immunoglobulin levels in premature and full-term infants. Am J Clin Pathol 1971;56:416-8.
6. Ballow M, Cates KL, Rowe JC, et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986;20:899-904.
7. Hodson WA. Normal and abnormal development of the lung. In: Polin A, Fox WW, eds. Fetal and neonatal physiology. 2nd ed. Philadelphia: Saunders, 1998.
8. Fanaroff AA, Wright LL, Stevenson DK, et al. Very-low-birth- weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, May 1991 through December 1992. Am J Obstet Gynecol 1995;173: 1423-31.
9. Northway WH Jr., Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane disease. N Engl J Med 1967;276:357-68.
10. Tooley WH. Epidemiology of bronchopulmonary dysplasia. J Pediatr 1979;95:851-8.
11. Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527-32.
12. Jobe AJ. The new BPD: An arrest of lung development. Pediatr Res 1999;46:641-3.
13. Hack M, Flannery DJ, Schluchter M, et al. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 2002;346:149-57.
14. Davis PG, Thorpe K, Roberts R, et al. Evaluating "old" definitions for the "new" bronchopulmonary dysplasia. J Pediatr 2002;140:555-60.
15. Bancalari EH. Neonatal chronic lung disease in neonatal- perinatal medicine. In: Fanaroff AA, Martin RJ, eds. Diseases of the fetus and infant. 7th ed. Philadelphia: Mosby, 2001.
16. Evans M, Palta M, Sadek M, et al. Associations between family history of asthma, bronchopulmonary dysplasia, and childhood asthma in very low birth weight children. Am J Epidemiol 1998;148:460-6.
17. Goldman SL, Gerhardt T, Sonni R, et al. Early prediction of chronic lung disease by pulmonary function testing. J Pediatr 1983;102:613-7.
18. Nilsson R, Grossmann G, Robertson B. Lung surfactant and the pathogenesis of neonatal bronchiolar lesions induced by artificial ventilation. Pediatr Res 1978;12:249-55.
19. Robertson B. The evolution of neonatal respiratory distress syndrome into chronic lung disease. Eur Respir J 1989;2: 33S-37S.
20. Thibeault DW, Mabry SM, Ekekezie II, et al. Lung elastic tissue maturation and perturbations during the evolution of chronic lung disease. Pediatrics 2000;106:1452-9.
21. Ozdemir A, Brown MA, Morgan WJ. Markers and mediators of inflammation in neonatal lung disease. Pediatr Pulmonol 1997;23:292-306.
22. Kraybill EN, Runyan DK, Bose CL, et al. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams. J Pediatr 1989;115:115-20.
23. Garland JS, Buck RK, Allred EN, et al. Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome. Arch Pediatr Adolesc Med 1995;149:617-23.
24. Dreyfuss D, Saumon G. Role of tidal volume, FRC, and end-inspiratory volume in the development of pulmonary edema following mechanical ventilation. Am Rev Respir Dis 1993;148:1194-203.
25. Nievas FF, Chernick V. Bronchopulmonary dysplasia (chronic lung disease of infancy): an update for the pediatrician. Clin Pediatr 2002;41:77-85.
26. Kamper J. Early nasal continuous positive airway pressure and minimal handling in the treatment of very-low-birthweight infants. Biol Neonate 1999;76:22-8.
27. Bancalari EH. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am J Perinatol 2001;18: 1-9.
28. Suresh GK, Davis JM, Soll RF. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database Syst Rev 2001;1: CD001968.
29. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2000;2:CD000501.
30. Phelps DL. Current perspectives on vitamin E in infant nutrition. Am J Clin Nutr 1987;46:187-91.
31. Wheater M, Rennie JM. Poor prognosis after prolonged ventilation for bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed 1994;71:F210-11.
32. Overstreet DW, Jackson JC, van Belle G, et al. Estimation of mortality risk in chronically ventilated infants with bronchopulmonary dysplasia. Pediatrics 1991;88:1153-60.
33. Sauve RS, Singhal N. Long-term morbidity of infants with bronchopulmonary dysplasia. Pediatrics 1985;76:725-33.
34. Robertson CMT, Etches PC, Goldson E, Kyle JM. Eight-year school performance, neurodevelopmental, and growth outcome of neonates with bronchopulmonary dysplasia: a comparative study. Pediatrics 1992;89:365-72.
35. Greenough A. Measuring respiratory outcome. Semin Neonatol 2000;5:119-26.
36. Meert K, Heidemann S, Abella B, et al. Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 1990;18:1357-9.
37. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212-19.
38. Langley JM, LeBlanc JC, Wang EE, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada study. Pediatrics 1997;100:943-6.
39. Behrendt CE, Decker MD, Burch DJ, et al. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr 1998;157:215-20.
40. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137:865-70.
41. Berner R, Schwoerer F, Schumacher RF, et al. Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr 2001;160:541-7.
42. Weigl JA, Puppe W, Schmitt HJ. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis 2001;20:452-9.
43. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991;88:527-32.
44. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants. Pediatrics 1998;102:531-7.
45. Yuksel B, Greenough A. Birth weight and hospital readmission of infants born prematurely. Arch Pediatr Adolesc Med 1994;148:384-8.
46. Nachman SA, Navaie-Waliser M, Quershi MZ. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow-up. Pediatrics 1997;6: 1-6.
47. Emond AM, Howat P, Evans JA, et al. The effects of housing on the health of preterm infants. Paediatr Perinat Epidemiol 1997;11:228-39.
48. Joffe S, Escobar GJ, Black SB, et al. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999;104:894-9.
49. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: Hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000;154:55-61.
50. Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001;20: 874-9.
51. Law BJ, de Carvalho V. Variation by gestational age in the rate of hospitalization of Canadian infants for LRTI due to RSV. Pediatr Infect Dis J 1993;12:659-63.
52. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
53. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
54. Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalization for RSV infection. Arch Dis Child 2001;85:463-8.
55. Imaizumi S, et al. Severity of RSV infection in hospitalized premature infants: the effects of gestational age and immune prophylaxis with palivizumab [Abstract 2311]. Presented at the Pediatric Academic Societies' 2001 Annual Meeting, Baltimore, April 28 to May 1, 2001.
56. Wang EE, Law BJ, Robinson JL, et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics 1997;99:E9.
57. Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children. J Infect Dis 2001;183:16-22.
58. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children: Pediatric Collaborative Network on Infections in Canada. J Pediatr 1992;121:348-54.
59. Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847-52.